Here, we explain how this programme resulted in the invention and continuing enhancement of Glivec イクスタンジ（エンザルタミド） (Gleevec in The us), the first selective tyrosine-kinase inhibitor being accredited for the remedy of the most cancers. ●医療関係者向けですが、一般の方々にも理解しやすいように